Translating Aortic Stenosis Guidelines Into Practice: Evidence-Based Decisions for the Heart Team
Recent updates to the ESC Valvular Heart Disease (VHD) Guidelines represent a significant step forward in the management of aortic stenosis (AS), reflecting ongoing advances in transcatheter aortic valve implantation (TAVI) and expanding evidence across a wide range of patient populations. For the multidisciplinary heart team, the key challenge is translating these evolving recommendations into real-world practice through informed, patient-centred decision-making.
This educational programme offers a concise, evidence-based update on current approaches to aortic stenosis management. Through a series of focused presentations and expert-led discussions, Prof Ole De Backer (Rigshospitalet, Copenhagen, DK) and Dr Angela McInerney (Galway University Hospital, Galway, IE) will explore the latest guideline updates, review pivotal clinical trial data and discuss their implications for daily practice. This programme highlights practical strategies for patient selection, referral pathways and lifetime management.
Your feedback helps us improve medical education and measure impact on clinical practice.
Learning Objectives
- Recall recent guideline recommendations for the management of aortic stenosis
- Summarise the evidence supporting TAVI across the sub-groups of aortic stenosis, age and surgical risk
- Develop an expert guided approach to patient selection and referral for TAVI
- Adopt an evidence-based approach for the lifetime management of younger patients with aortic stenosis
Target Audience
- Interventional Cardiologists
- General Cardiologists
- Imaging Specialists
- Nurses
- Physicians in Training
More from this programme
Part 1
Dr Angela McInerney provides an overview of the latest ESC guideline updates in aortic stenosis, including age cutoffs for TAVI vs SAVR, multimodality imaging and sex-specific considerations. Discussion explores how these changes impact real-world practice for patients, referrers and implanting teams.
Part 2
Prof Ole De Backer gives a review of landmark TAVI trials. Discussion summarises evidence across risk levels, younger patient populations and valve durability.
| 1 session | |
| A Review of the Evidence | Watch now |
Part 3
Dr Angela McInerney presents a case and with Prof Ole De Backer they discuss evaluating and referring patients for TAVI. This chapter covers a practical referral checklist, integrating patient preferences, recognising underrepresented groups and optimising the patient journey to ensure timely, appropriate, and personalised care decisions.
Part 4
In this expert-led insights sessions cover how HCPs can implement new guideline recommendations in practice. The discussion focuses on lifetime management, including valve-in-valve strategies, bicuspid AS, CT and coronary access considerations and balancing age versus life expectancy in treatment planning.
Faculty Biographies
Ole De Backer
Interventional Cardiologist
Prof Ole De Backer is an internationally renowned interventional cardiologist working at Rigshospitalet, Copenhagen University Hospital, Denmark and is an expert in structural heart interventions – among others transcatheter heart valve interventions, percutaneous left atrial appendage closure and thoracic endovascular aortic repair. Special areas of interest are the development and adoption of a fully percutaneous, minimal invasive approach for different structural heart interventions and the use of advanced cardiac imaging tools for planning and guidance of these interventions. He is actively involved and leading several research projects in the field of transcatheter heart valves and percutaneous left atrial appendage closure.
Angela McInerney
Interventional Cardiologist
Dr Angela McInerney is an Interventional Cardiologist at Galway University Hospital, Galway, IE. Prior to this she took up an Interventional Fellowship and research position at Hospital Clinico San Carlos, Madrid, ES.
Her specialist interests include complex coronary artery disease and percutaneous treatment of structural heart disease.